Survival Comparison between Melanoma Patients Treated with Patient-Specific Dendritic Cell Vaccines and Other Immunotherapies Based on Extent of Disease at the Time of Treatment
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-11 / Biomedicines 2019 Oct;7(4)Dendritic Cell Vaccination in Metastatic Melanoma Turns „Non-T Cell Inflamed“ Into „T-Cell Inflamed“ Tumors
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-10-09 / Front Immunol 2019;10:2353Immune Dysfunctions and Immunotherapy in Colorectal Cancer: The Role of Dendritic Cells
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2019-10-03 / Cancers (Basel) 2019 Oct;11(10)Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
/in Brain Tumors in Children, Dendritic Cells, International Publications /von 2019-09-19 / Cancers (Basel) 2019 Sep;11(9)Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications /von 2019-09-19 / Cancers (Basel) 2019 Sep;11(9)Past, Current, and Future of Immunotherapies for Prostate Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2019-09-11 / Front Oncol 2019;9:884The current state of immunotherapy for gliomas: an eye toward the future
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2019-09-01 / J. Neurosurg. 2019 09;131(3):657-666Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2019-08-30 / Biomedicines 2019 Aug;7(3)Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination
/in Dendritic Cells, International Publications /von 2019-08-27 / Front Oncol 2019;9:811
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de